Adult Subjects With Uncontrolled Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 149 participants.

Also called NCT02317796

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 149 participants (enrolled count) (from the registry)
Sponsor
Melior Pharmaceuticals (from the registry)
Registry
  • NCT NCT02317796
Other papers using this trial's data
  • A novel non-PPARgamma insulin sensitizer: MLR-1023 clinicalproof-of-concept in type 2 diabetes mellitus Journal of diabetes and its complications, 2020-05 DOI, PubMed 32019723

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02317796. Randomized; triple masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2015-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Adult Subjects With Uncontrolled Type 2 Diabetes
Intervention (Drug)
MLR-1023
Lead sponsor
Melior Pharmaceuticals (class: other)
Collaborator
Bukwang Pharmaceutical, Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct02317796
Content hash
13f5211840e8b6324adc83952cff1695ccdcf0553dc02c2c6703812793c76cd8